Trial Designs

You have free access to this content

Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial

  1. David E. Kandzari MD1,*,
  2. Deepak L. Bhatt MD, MPH2,
  3. Paul A. Sobotka MD3,10,
  4. William W. O'Neill MD4,
  5. Murray Esler MBBS, PhD5,
  6. John M. Flack MD, MPH6,
  7. Barry T. Katzen MD7,
  8. Martin B. Leon MD8,
  9. Joseph M. Massaro PhD9,
  10. Manuela Negoita MD10,
  11. Suzanne Oparil MD11,
  12. Krishna Rocha-Singh MD12,
  13. Craig Straley10,
  14. Raymond R. Townsend MD13,
  15. George Bakris MD14

Article first published online: 9 MAY 2012

DOI: 10.1002/clc.22008

Issue

Clinical Cardiology

Clinical Cardiology

Volume 35, Issue 9, pages 528–535, September 2012

Additional Information

How to Cite

Kandzari, D. E., Bhatt, D. L., Sobotka, P. A., O'Neill, W. W., Esler, M., Flack, J. M., Katzen, B. T., Leon, M. B., Massaro, J. M., Negoita, M., Oparil, S., Rocha-Singh, K., Straley, C., Townsend, R. R. and Bakris, G. (2012), Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial. Clin Cardiol, 35: 528–535. doi: 10.1002/clc.22008

Author Information

  1. 1

    Piedmont Heart Institute, Atlanta, GA

  2. 2

    VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA

  3. 3

    The Ohio State University, Columbus, OH

  4. 4

    Miller School of Medicine, University of Miami, Miami, FL

  5. 5

    Baker IDI Heart and Diabetes Institute, Melbourne, Australia

  6. 6

    Wayne State University and the Detroit Medical Center, Detroit, MI

  7. 7

    Baptist Cardiac and Vascular Institute, Miami, FL

  8. 8

    New York Presbyterian Hospital, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

  9. 9

    Boston University School of Public Health, Boston, MA

  10. 10

    Medtronic CardioVascular, Santa Rosa, CA

  11. 11

    University of Alabama at Birmingham, Birmingham, AL

  12. 12

    Prairie Education and Research Cooperative, Springfield, IL

  13. 13

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

  14. 14

    The University of Chicago Medicine, Chicago, IL

*Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Publication History

  1. Issue published online: 10 SEP 2012
  2. Article first published online: 9 MAY 2012
  3. Manuscript Revised: 11 APR 2012
  4. Manuscript Received: 27 FEB 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (265K)

References

  • 1.
    Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365: 217–223.
  • 2.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics 2012 update; a report from the American Heart Association. Circulation. 2012;125:e12–e230.
  • 3.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
  • 4.
    Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466–472.
  • 5.
    Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control—continued disparities in adults: United States, 2005–2006. NCHS Data Brief No. 3. Hyattsville, MD: National Center for Health Statistics; 2008.
  • 6.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–2050.
  • 7.
    Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52: 1749–1757.
  • 8.
    Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999–2010.
  • 9.
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–2788.
  • 10.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
  • 11.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–1080.
  • 12.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526.
  • 13.
    Esler M, Jennings G, Korner P, et al. Total and organ-specific noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens A. 1984:6:507–521.
  • 14.
    Esler M, Jennings G, Korner P, et al. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.
  • 15.
    Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–1762.
  • 16.
    Narkiewicz K, Pesek CA, Kato M, et al. Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension. 1998;32:1039–1043.
  • 17.
    Vollenweider P, Tappy L, Randin D, et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92:147–154.
  • 18.
    Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097–3101.
  • 19.
    Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909–920.
  • 20.
    Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106: 1974–1979.
  • 21.
    DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–R253.
  • 22.
    Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension. Results in 1,266 cases. JAMA. 1953;152:1501–1504.
  • 23.
    Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension. A review of 74 patients. Br J Surg. 1954;41:382–392.
    Direct Link:
  • 24.
    Smithwick RH. Surgical treatment of hypertension. Am J Med. 1948:4:744–759.
  • 25.
    Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217–222.
  • 26.
    Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918.
  • 27.
    Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009; 361:932–934.
  • 28.
    Krum H, Sobotka P, Mahfoud F, et al. Device-Based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209–215.
  • 29.
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.
  • 30.
    Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–917.
  • 31.
    Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–1909.
  • 32.
    Schlaich MP, Krum H, Sobotka PA, et al. Renal denervation and hypertension. Am J Hypertension. 2011;24:635–642.
  • 33.
    Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882–1888.
  • 34.
    Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100:1049–1057.
  • 35.
    Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123: 1940–1946.
  • 36.
    Schlaich MP, Straznicky N, Grima M, et al Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991–996.
View Full Article (HTML) Get PDF (265K)